Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children

Pediatric Hematology and Oncology

Volumn 29, Issue 5, 2012, Pages 485-493

  Elalfy, Mohsen S ^a,c   Elbarbary, Nancy S ^a   Eldebeiky, Mohamed S ^b   El Danasoury, Azza S ^b  

^a Ain Shams University   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c NONE   (Egypt)

Author keywords

Bleeding complication; Circumcision; Factor replacement; FVIII inhibitor; Severe hemophilia A

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; GELATIN SPONGE; HEMOSTATIC AGENT; TRANEXAMIC ACID;

ARTICLE; CHILD; CIRCUMCISION; CLINICAL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; GENE MUTATION; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFANT; INTERVENTION STUDY; INTRON; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE PROCEDURE; PILOT STUDY; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SINGLE DRUG DOSE; WOUND DRESSING;

EID: 84864849940     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.704624     Document Type: Article

References (35)

1. Kavakli K, AledortM. Circumcision and haemophilia: A perspective. Haemophilia. 1998;4:1-3.
2. Gatrad AR, Sheikh A, Jacks H. Religious circumcision and the human rights act. Arch Dis Child. 2002;86(2):76-78.
3. Meijer B, Butzelaar RM. Circumcision from a historical perspective. Ned Tijdschr Geneeskd. 2000;144(52):2504-2508.
4. Kavakli K,Kurugol Z,GoksenD,Nisli G. Should hemophiliac patients be circumcised? PediatrHematol Oncol. 2000;17:149-153.
5. Karaman MI, Zulfikar B, Caskurlu T, Ergenekon E. Circumcision in hemophilia: A cost-effective method using a novel device. J Pediatr Surg. 2004;39:1562-1564.
6. Tazi I. Fibrin glue, hemophilia, and circumcision in low-income countries. J Pediatr Surg. 2011;46(2):428-489.
7. Goudemand J, Rothschild C, Demiguel V, et al. FVIII-LFB and recombinant FVIII study groups. Blood. 2006;107(1):46-51.
8. Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report. Haemophilia. 2010;16:747-766.
9. Gouw SC, van den Berg HM, Le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: Amulticentre cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5:1383-1390.
10. El Alfy MS, Tantawy AA, Ahmed MH, Abdin IA. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction. Haemophilia. 2000;6(6):635-638.
11. Seyednejad H, Imani M, Jamieson T, Seifalian AM. Topical haemostatic agents. Br J Surg. 2008;95:1197-1225.
12. Gray RH,KigoziG, Serwadda D, et al.Male circumcision for HIVprevention inmen in Rakai,Uganda: A randomised trial. Lancet. 2007;369:657-666.
13. Gesundheit B, Greenberg D, Walfish S, et al. Infectious complications with herpes virus after ritual Jewish circumcision: A historical and cultural analysis. Harefuah. 2005;144(2):126-132, 149, 148.
14. Yilmaz D, Akin M, Ay Y, et al. A single centre experience in circumcision of haemophilia patients: Lzmir protocol. Haemophilia. 2010;16(6):888-891.
15. Rodriguez V, Titapiwatanakun R, Moir C, et al. To circumcise or not to circumcise Circumcision in patients with bleeding disorders. Haemophilia. 2010;16(2):272-276.
16. Shittu OB, Shokunbi WA. Circumcision in haemophiliacs: The Nigerian experience. Haemophilia. 2001;7:532-536.
17. Avanoglu A, Celik A, Ulman IC, et al. Gökdemir safer circumcision in patients with haemophilia: The use of fibrin glue for local haemostasis. BJU Int. 1999;83:91-94.
18. Szpalski M, Gunzburg R, Sztern B. An overview of blood-sparing techniques used in spine surgery during the perioperative period. Eur Spine J. 2004;13(Suppl 1):S18-S27.
19. Oner AF, Doǧan M, Kaya A, et al. New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor. Clin Appl Thromb Hemost. 2010;16(6):705-707.
20. Spotnitz WD. Fibrin sealant: Past, present, and future: A brief review. World J Surg. 2010;34(4):632-634.
21. Haghpanah S, Vafafar A, Golzadeh MH, et al. Use of Glubran 2 and Glubran tissue skin adhesive in patients with hereditary bleeding disorders undergoing circumcision and dental extraction. Ann Hematol. 2011;90(4):463-468.
22. CipilH, Kosar A, Kaya A, et al. In vivo hemostatic effect of the medicinal plant extract Ankaferd blood stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost. 2009;15(3):270-276.
23. DoganDogan OF,Ozyurda U,UymazOK, et al.New anticoagulant agent for CABG surgery. Eur J Clin Invest. 2008;38(5):341.
24. Martinowitz U, Varon D, Jonas P, et al. Circumcision in hemophilia: The use of fibrin glue for local haemostasis. J Urol. 1992; 148:855-857.
25. Martinowitz U, Schulman S. Fibrin sealant in surgery of patients with a hemorrhagic diathesis. Thromb Haemost. 1995;74:486-492.
26. Mintz PD,Mayers L, AveryN, et al. Fibrin sealant: Clinical use and the development of the University of Virginia Tissue Adhesive Center.Ann Clin Lab Sci. 2001;31:108-118.
27. Ghosh K, Jijina F, Shetty S, et al. First-time development of FVIII inhibitor in haemophilia patients during the postoperative period. Haemophilia. 2002;8:776-780.
28. Sharathkumar A, Lillicrap D, Blanchette S, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development inmild haemophilia A. J Thromb Haemost. 2003;1:1228-1236.
29. White GC II, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A. Thromb Haemost. 1997;77:660-667.
30. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost. 1997;78:256-260.
31. Santagostino E,MancusoME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: Case-control study. Br J Haematol. 2005;130:422-427.
32. Negrier C, Shapiro A, Berntorp E, et al. Surgical evaluation of recombinant factor VII prepared using a plasma/albumin-freemethod: Efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008;100:217-223.
33. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8:279-289.
34. Maclean PS, Richards M, Williams M, et al. Paediatric working party of UKHCDO treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia. 2011;17(2):282-287.
35. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998;4(4):558-563.